BRPI0513283A - combinações de estatina com broncodilatadores - Google Patents

combinações de estatina com broncodilatadores

Info

Publication number
BRPI0513283A
BRPI0513283A BRPI0513283-5A BRPI0513283A BRPI0513283A BR PI0513283 A BRPI0513283 A BR PI0513283A BR PI0513283 A BRPI0513283 A BR PI0513283A BR PI0513283 A BRPI0513283 A BR PI0513283A
Authority
BR
Brazil
Prior art keywords
combinations
statin
bronchodilator combinations
bronchodilator
broncodilators
Prior art date
Application number
BRPI0513283-5A
Other languages
English (en)
Inventor
Bertil Lindmark
Anders Ingemar
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0513283A publication Critical patent/BRPI0513283A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMBINAçõES DE ESTATINA COM BRONCODILATADORES A presente invenção proporciona medicamentos compreendendo combinações de broncodilatadores, glicocorticosteróides e inibidores de HMG-CoA redutase, que são de utilidade no tratamento de distúrbios respiratórios, como a doença pulmonar obstrutiva crónica (COPD)
BRPI0513283-5A 2004-07-15 2005-06-20 combinações de estatina com broncodilatadores BRPI0513283A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0415789.7A GB0415789D0 (en) 2004-07-15 2004-07-15 Novel combination
PCT/GB2005/002413 WO2006008437A1 (en) 2004-07-15 2005-06-20 Combinations of stattins with bronchodilators

Publications (1)

Publication Number Publication Date
BRPI0513283A true BRPI0513283A (pt) 2008-05-06

Family

ID=32893577

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513283-5A BRPI0513283A (pt) 2004-07-15 2005-06-20 combinações de estatina com broncodilatadores

Country Status (14)

Country Link
US (1) US20080004247A1 (pt)
EP (1) EP1773319A1 (pt)
JP (1) JP2008506674A (pt)
CN (1) CN1984653A (pt)
AU (1) AU2005263883A1 (pt)
BR (1) BRPI0513283A (pt)
CA (1) CA2573393A1 (pt)
GB (1) GB0415789D0 (pt)
IL (1) IL180423A0 (pt)
MX (1) MX2007000424A (pt)
NO (1) NO20070651L (pt)
RU (1) RU2007101518A (pt)
WO (1) WO2006008437A1 (pt)
ZA (1) ZA200700071B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007149245A (ru) 2005-06-02 2009-07-20 Те Риджентс Оф Те Юниверсити Оф Колорадо (Us) Способ снижения риска развития рака и предраковой дисплазии
JP5336847B2 (ja) * 2006-06-29 2013-11-06 第一三共株式会社 スタチンによる慢性閉塞性肺疾患治療
PT2359826E (pt) * 2006-07-05 2014-01-20 Takeda Gmbh Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
US20100048693A1 (en) * 2006-12-04 2010-02-25 The Regents Of The University Of Colorado, A Body Corporate Treatment of COPD
US20150174157A1 (en) * 2007-06-15 2015-06-25 Kaohsiung Medical University INHALED NO DONOR PIPERAZINYL DERIVATIVE PREVENTING ALLERGIC PULMONARY VASCULAR AND BRONCHIAL INFLAMMATION BY REDUCING VEGF AND RESTORING eNOS IN HYPOXIC PULMONARY ARTERY
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
ES2604705T3 (es) 2010-03-31 2017-03-08 Ono Pharmaceutical Co., Ltd. Agente preventivo y/o remedio para el síndrome mano-pie
MX2013000642A (es) * 2010-07-16 2013-04-03 Cipla Ltd Composiciones farmaceuticas.
CN104363910A (zh) 2012-03-14 2015-02-18 日本株式会社Ltt生物医药 慢性阻塞性肺疾病改善剂
KR20150135328A (ko) * 2013-04-01 2015-12-02 풀매트릭스 인코퍼레이티드 티오트로피움 건조 분말
WO2014182928A2 (en) 2013-05-08 2014-11-13 Board Of Regents, The University Of Texas System Stat6 inhibitors
EP4122469A1 (en) * 2014-03-28 2023-01-25 Paul Maes Composition comprising cyclodextrin and budesonide derivatives for the treatment and prophylaxis of pulmonary inflammations
WO2017117210A1 (en) 2015-12-30 2017-07-06 Visiongate, Inc. System and method for automated detection and monitoring of dysplasia and administration of chemoprevention
CA3090881A1 (en) 2018-03-01 2019-09-06 Comfort Concepts, LLC Seating pad with woven cover
WO2020028124A1 (en) * 2018-07-31 2020-02-06 Wen Tan NEW USE OF CARBAMATE β PHENYLETHANOLAMINE ANALOGUES FOR ENHANCING INTRACELLULAR CLEARANCE OF LDL CHOLESTEROL AND FOR COMBINING THERAPY WITH STATINS TO ENHANCE THE EFFICACY AND REDUCE ADVERSE EFFECTS
CN109498625B (zh) * 2018-12-29 2021-04-16 温州医科大学附属第一医院 一种治疗慢性阻塞性肺疾病的药物组合物及其制备方法
CN115337311B (zh) * 2022-09-26 2023-05-09 南京恒道医药科技股份有限公司 一种治疗呼吸系统疾病的组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US20010006656A1 (en) * 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
US20030018040A1 (en) * 2000-02-10 2003-01-23 Yasuo Sugiyama Tnf-alpha inhibitors
US20050119330A1 (en) * 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases

Also Published As

Publication number Publication date
GB0415789D0 (en) 2004-08-18
AU2005263883A1 (en) 2006-01-26
RU2007101518A (ru) 2008-08-20
ZA200700071B (en) 2008-04-30
WO2006008437A1 (en) 2006-01-26
US20080004247A1 (en) 2008-01-03
EP1773319A1 (en) 2007-04-18
CA2573393A1 (en) 2006-01-26
MX2007000424A (es) 2007-03-07
NO20070651L (no) 2007-02-05
CN1984653A (zh) 2007-06-20
IL180423A0 (en) 2008-03-20
JP2008506674A (ja) 2008-03-06

Similar Documents

Publication Publication Date Title
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
WO2008049000A3 (en) Combination therapy for pulmonary arterial hypertension
BR112013008140A2 (pt) "compostos imidazotriazinona".
CR7043A (es) Derivados de eteres utiles como ganetes inhibidores de las isozimas pde4
GT200800123A (es) Compuestos mimeticos de lisina modificados
WO2007044763A3 (en) System and method for detecting fraudulent transactions
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2008115469A3 (en) Role of hedgehog signaling in atherosclerosis and cardiovascular disease
WO2009027346A3 (de) 17beta-hydroxysteroid-dehydrogenase-typ1-inhibitoren zur behandlung hormonabhängiger erkrankungen
WO2010088368A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2009098682A3 (en) Methods and compositions for treatment of mitochondrial disorders
TW200833667A (en) Chemical process
ECSP088287A (es) Una combinación de compuestos que puede ser utilizada en el tratamiento de enfermedades respiratorias, especialmente enfermedad pulmonar obstructiva crónica (epoc) y asma
WO2012061788A3 (en) Tetrameric alpha-synuclein as biomarkers
CY1114742T1 (el) Συνδυασμος του αναστολεα αναγωγασης ημg-coa ροζουβαστατινης με αναστολεα φωσφοδιεστερασης 4, οπως η ροφλουμιλαστη, ν-οξειδιο ροφλουμιλαστης για τη θεραπεια φλεγμονωδων πνευμονικων νοσων
BRPI0909566A2 (pt) Linhagem de h. Polymorpha recombinante, processo de elaboração de etanol que compreende o cultivo da linhagem de h. Polymorpha recombinante e ácido nucleico recombinante
WO2007021989A3 (en) Interlayers comprising an ultraviolet curable layer
DE502005004826D1 (de) Verdampfer, beatmungsgerät sowie verdampfungsverfahren
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2006060189A3 (en) Curable silicone compositions incorporating a fluorescent detection system
WO2008044076A3 (en) Therapy targeting cathepsin s
ECSP099311A (es) Farmaco combinado
EP1917579A4 (en) SCHEME PACKING, DISTRIBUTION AND AVAILABILITY
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof
WO2009001144A3 (en) Pharmaceutical aerosol compositions comprising fluticasone

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]